City Therapeutics broke cover in October with a $135 million Series A and the opportunity for executive chairman John ...
Repare Therapeutics pauses gynecologic cancer drugs lunresertib & camonsertib, shifts focus to early-stage assets RP-1664 & RP-3467 amid cost-cutting measures.
Marea Therapeutics reports MAR001 reduced remnant cholesterol by ~50% in Phase 2a trial; plans Phase 2b within 6 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback